Glioblastoma, the most aggressive high-grade glioma, is a devastating primary brain tumor resistant to conventional therapies, and the second most common cause of death from intracranial disease.
Approximately 25,000 patients are diagnosed in the United States and Europe with glioblastoma each year. After initial treatment with surgery, radiation, and chemotherapy, few options are available for patients who experience tumor progression. Many therapies targeting specific molecular pathways, even when used in combination, have failed to improve overall survival. Thus, it’s critical that novel drugs are developed that have a positive impact on the course of this aggressive disease.
In an effort to address this critical medical need, DNAtrix has developed, DNX-2401, which offers a new mode of attack for treating patients with glioblastoma.
DNX-2401 + Pembrolizumab
Phase 2 collaboration study with Merck to evaluate the efficacy and safety of DNX-2401 in combination with pembrolizumab (KEYTRUDA), Merck’s anti-PD-1 therapy, for patients with recurrent glioblastoma.
DNX-2401 + Temozolomide
Study D24GBM is a Phase 1b study evaluate the safety and efficacy of DNX-2401 followed by treatment with temozolomide (Temodar). Adult subjects diagnosed with glioblastoma or gliosarcoma that have experienced disease progression after initial treatment may be eligible.
DNX-2401 ± Interferon Gamma
Study 2401BT-IFN-001 (TARGET-1) is a Phase 1b study evaluating the safety and efficacy of administering DNX-2401 as monotherapy or DNX-2401 followed by treatment with interferon gamma (Actimmune). Adult subjects diagnosed with glioblastoma or gliosarcoma that have experienced disease progression after initial treatment may be eligible.